Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Equivalents (2019 - 2025)

C4 Therapeutics' Cash & Equivalents history spans 7 years, with the latest figure at $74.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 34.42% year-over-year to $74.6 million; the TTM value through Dec 2025 reached $74.6 million, up 34.42%, while the annual FY2025 figure was $74.6 million, 34.42% up from the prior year.
  • Cash & Equivalents reached $74.6 million in Q4 2025 per CCCC's latest filing, up from $58.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $281.1 million in Q2 2021 to a low of $29.8 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $81.0 million, with a median of $60.3 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: tumbled 79.62% in 2022, then soared 325.46% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $76.1 million in 2021, then plummeted by 60.91% to $29.8 million in 2022, then skyrocketed by 325.46% to $126.6 million in 2023, then plummeted by 56.16% to $55.5 million in 2024, then surged by 34.42% to $74.6 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Cash & Equivalents are $74.6 million (Q4 2025), $58.8 million (Q3 2025), and $78.2 million (Q2 2025).